Literature DB >> 8816752

Analysis of estrogen receptor transcriptional enhancement by a nuclear hormone receptor coactivator.

E M McInerney1, M J Tsai, B W O'Malley, B S Katzenellenbogen.   

Abstract

The estrogen receptor (ER), a member of a large superfamily of nuclear hormone receptors, is a ligand-inducible transcription factor that regulates the expression of estrogen-responsive genes. The ER, in common with other members of this superfamily, contains two transcription activation functions (AFs)--one located in the amino-terminal region (AF-1) and the second located in the carboxyl-terminal region (AF-2). In most cell contexts, the synergistic activity of AF-1 and AF-2 is required for full estradiol (E2)-stimulated activity. We have previously shown that a ligand-dependent interaction between the two AF-containing regions of ER was promoted by E2 and the antiestrogen trans-hydroxytamoxifen (TOT). This interaction, however, was transcriptionally productive only in the presence of E2. To explore a possible role of steroid receptor coactivators in transcriptional synergism between AF-1 and AF-2, we expressed the amino terminal (AF-1-containing) and carboxyl-terminal (AF-2-containing) regions of ER as separate polypeptides in mammalian cells, along with the steroid receptor coactivator-1 protein (SRC-1). We demonstrate that SRC-1, which has been shown to significantly increase ER transcriptional activity, enhanced the interaction, mediated by either E2 or TOT, between the AF-1-containing and AF-2-containing regions of the ER. However, this enhanced interaction resulted in increased transcriptional effectiveness only with E2 and not with TOT, consistent with the effects of SRC-1 on the full-length receptor. Our results suggest that after ligand binding, SRC-1 may act, in part, as an adapter protein that promotes the integration of amino- and carboxyl-terminal receptor functions, allowing for full receptor activation. Potentially, SRC-1 may be capable of enhancing the transcriptional activity of related nuclear receptor superfamily members by facilitating the productive association of the two AF-containing regions in these receptors.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8816752      PMCID: PMC38337          DOI: 10.1073/pnas.93.19.10069

Source DB:  PubMed          Journal:  Proc Natl Acad Sci U S A        ISSN: 0027-8424            Impact factor:   11.205


  27 in total

1.  Transactivation functions facilitate the disruption of chromatin structure by estrogen receptor derivatives in vivo.

Authors:  T A Pham; Y P Hwung; D P McDonnell; B W O'Malley
Journal:  J Biol Chem       Date:  1991-09-25       Impact factor: 5.157

2.  Estrogen receptor-associated proteins: possible mediators of hormone-induced transcription.

Authors:  S Halachmi; E Marden; G Martin; H MacKay; C Abbondanza; M Brown
Journal:  Science       Date:  1994-06-03       Impact factor: 47.728

3.  Interaction of proteins with transcriptionally active estrogen receptors.

Authors:  V Cavaillès; S Dauvois; P S Danielian; M G Parker
Journal:  Proc Natl Acad Sci U S A       Date:  1994-10-11       Impact factor: 11.205

Review 4.  Molecular mechanisms of action of steroid/thyroid receptor superfamily members.

Authors:  M J Tsai; B W O'Malley
Journal:  Annu Rev Biochem       Date:  1994       Impact factor: 23.643

5.  Mutagenesis of cysteines in the hormone binding domain of the human estrogen receptor. Alterations in binding and transcriptional activation by covalently and reversibly attaching ligands.

Authors:  J C Reese; B S Katzenellenbogen
Journal:  J Biol Chem       Date:  1991-06-15       Impact factor: 5.157

6.  The carboxy-terminal F domain of the human estrogen receptor: role in the transcriptional activity of the receptor and the effectiveness of antiestrogens as estrogen antagonists.

Authors:  M M Montano; V Müller; A Trobaugh; B S Katzenellenbogen
Journal:  Mol Endocrinol       Date:  1995-07

7.  Human estrogen receptor transactivational capacity is determined by both cellular and promoter context and mediated by two functionally distinct intramolecular regions.

Authors:  M T Tzukerman; A Esty; D Santiso-Mere; P Danielian; M G Parker; R B Stein; J W Pike; D P McDonnell
Journal:  Mol Endocrinol       Date:  1994-01

8.  Transcriptional activation by the estrogen receptor requires a conformational change in the ligand binding domain.

Authors:  J M Beekman; G F Allan; S Y Tsai; M J Tsai; B W O'Malley
Journal:  Mol Endocrinol       Date:  1993-10

9.  The N-terminal part of TIF1, a putative mediator of the ligand-dependent activation function (AF-2) of nuclear receptors, is fused to B-raf in the oncogenic protein T18.

Authors:  B Le Douarin; C Zechel; J M Garnier; Y Lutz; L Tora; P Pierrat; D Heery; H Gronemeyer; P Chambon; R Losson
Journal:  EMBO J       Date:  1995-05-01       Impact factor: 11.598

10.  Nuclear factor RIP140 modulates transcriptional activation by the estrogen receptor.

Authors:  V Cavaillès; S Dauvois; F L'Horset; G Lopez; S Hoare; P J Kushner; M G Parker
Journal:  EMBO J       Date:  1995-08-01       Impact factor: 11.598

View more
  49 in total

1.  Molecular determinants of the estrogen receptor-coactivator interface.

Authors:  H Y Mak; S Hoare; P M Henttu; M G Parker
Journal:  Mol Cell Biol       Date:  1999-05       Impact factor: 4.272

2.  Ligand-independent activation of oestrogen receptor alpha by caveolin-1.

Authors:  A Schlegel; C Wang; R G Pestell; M P Lisanti
Journal:  Biochem J       Date:  2001-10-01       Impact factor: 3.857

Review 3.  Mechanisms of resistance to hormonal treatment in breast cancer.

Authors:  P Eroles; A Bosch; B Bermejo; A Lluch
Journal:  Clin Transl Oncol       Date:  2010-04       Impact factor: 3.405

4.  Identification and structure-activity relationships of a novel series of estrogen receptor ligands based on 7-thiabicyclo[2.2.1]hept-2-ene-7-oxide.

Authors:  Pengcheng Wang; Jian Min; Jerome C Nwachukwu; Valerie Cavett; Kathryn E Carlson; Pu Guo; Manghong Zhu; Yangfan Zheng; Chune Dong; John A Katzenellenbogen; Kendall W Nettles; Hai-Bing Zhou
Journal:  J Med Chem       Date:  2012-02-21       Impact factor: 7.446

5.  The androgen receptor amino-terminal domain plays a key role in p160 coactivator-stimulated gene transcription.

Authors:  P Alen; F Claessens; G Verhoeven; W Rombauts; B Peeters
Journal:  Mol Cell Biol       Date:  1999-09       Impact factor: 4.272

6.  Steroid receptor coactivator-2 expression in brain and physical associations with steroid receptors.

Authors:  M A Yore; D Im; L K Webb; Y Zhao; J G Chadwick; H A Molenda-Figueira; S J Haidacher; L Denner; M J Tetel
Journal:  Neuroscience       Date:  2010-06-02       Impact factor: 3.590

7.  Bicyclic core estrogens as full antagonists: synthesis, biological evaluation and structure-activity relationships of estrogen receptor ligands based on bridged oxabicyclic core arylsulfonamides.

Authors:  Manghong Zhu; Chen Zhang; Jerome C Nwachukwu; Sathish Srinivasan; Valerie Cavett; Yangfan Zheng; Kathryn E Carlson; Chune Dong; John A Katzenellenbogen; Kendall W Nettles; Hai-Bing Zhou
Journal:  Org Biomol Chem       Date:  2012-11-21       Impact factor: 3.876

8.  Post-transcriptional regulation of human breast cancer cell proteome by unliganded estrogen receptor β via microRNAs.

Authors:  Giovanni Nassa; Roberta Tarallo; Giorgio Giurato; Maria Rosaria De Filippo; Maria Ravo; Francesca Rizzo; Claudia Stellato; Concetta Ambrosino; Marc Baumann; Niina Lietzèn; Tuula A Nyman; Alessandro Weisz
Journal:  Mol Cell Proteomics       Date:  2014-02-13       Impact factor: 5.911

9.  Steroid receptor coactivator-1 from brain physically interacts differentially with steroid receptor subtypes.

Authors:  Heather A Molenda-Figueira; Suzanne D Murphy; Katherine L Shea; Nora K Siegal; Yingxin Zhao; Joseph G Chadwick; Larry A Denner; Marc J Tetel
Journal:  Endocrinology       Date:  2008-06-19       Impact factor: 4.736

10.  Bibenzyl- and stilbene-core compounds with non-polar linker atom substituents as selective ligands for estrogen receptor beta.

Authors:  Michael Waibel; Meri De Angelis; Fabio Stossi; Karen J Kieser; Kathryn E Carlson; Benita S Katzenellenbogen; John A Katzenellenbogen
Journal:  Eur J Med Chem       Date:  2009-02-20       Impact factor: 6.514

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.